Evidence map›Paper›PMID 32566630›Full record

ArticleAnnals of translational medicine2020

High clinical impact of rapid susceptibility testing on CHROMID ESBL

Álvaro Romo-Ibáñez, Elisabeth Calatrava-Hernández, Blanca Gutiérrez-Soto, Mercedes Pérez-Ruiz, José María Navarro-Marí, José Gutiérrez-Fernández

Open access · diamondAbstract read
In one paragraph

Article in Annals of translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Álvaro Romo-IbáñezDepartment of Microbiology, School of Medicine, University of Granada-Instituto de Investigación Biosanitaria, Granada, Spain.
Elisabeth Calatrava-HernándezDepartment of Microbiology, Hospital Universitario Virgen de las Nieves-Instituto de Investigación Biosanitaria, Granada, Spain.
Blanca Gutiérrez-SotoFamily Medicine Unit, Health Center San Fernando, Badajoz, Spain.
Mercedes Pérez-RuizDepartment of Microbiology, Hospital Universitario Virgen de las Nieves-Instituto de Investigación Biosanitaria, Granada, Spain.
José María Navarro-MaríDepartment of Microbiology, Hospital Universitario Virgen de las Nieves-Instituto de Investigación Biosanitaria, Granada, Spain.
José Gutiérrez-FernándezDepartment of Microbiology, School of Medicine, University of Granada-Instituto de Investigación Biosanitaria, Granada, Spain.
Hospital Universitario Virgen de las Nieves · ESInstituto de Investigación Biosanitaria de Granada · ESUniversidad de Granada · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAntibiotic resistance is a serious public health challenge exacerbated by the widespread use of β-lactam and glycopeptide antibiotics. The identification of resistances is crucial, and CHROMID ESBL medium has been developed to detect enterobacteria with extended-spectrum β-lactamases (ESBL). The objective of this study was to evaluate the potential of this medium to detect other types of resistant bacteria.

methodsVancomycin, cefoxitin, imipenem, and cefepime disks were used to measure growth on CHROMID ESBL medium of β-lactam-resistant Gram-negative (83 with ESBL, 57 with carbapenemases, 35 with AmpC and 3

resultsRetrospective study: species grown on the medium exhibited different colors. Growth on the medium was observed for: all ESBL enterobacteria, which were susceptible to imipenem and cefoxitin; 95% of isolates with carbapenemases, mostly resistant to imipenem; 80% of those with AmpC; 86% of vancoR

conclusionsCHROMID ESBL medium permitted the differential growth of Gram-negative bacteria, many with ESBL and carbapenemases. ESBL enterobacteria were susceptible to imipenem, carbapenemase-producing microorganisms grew around the imipenem disk, and vancoR

Indexed as

CHROMID ESBL mediumchromogenic mediaMultiresistant bacteria

Identifiers

PMID32566630
PMCPMC7290529
OpenAlexW3012920953

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.